OLEMA PHARMACEUTICALS INC (OLMA) Forecast, Price Target & Analyst Ratings
NASDAQ:OLMA • US68062P1066
21.55 USD
-1.01 (-4.48%)
At close: Mar 6, 2026
21.55 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OLEMA PHARMACEUTICALS INC (OLMA).
Forecast Snapshot
Consensus Price Target
$46.73
+ 116.87% Upside
Next Earnings Forecast
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$0.54
Revenue Estimate
ChartMill Buy Consensus
86.67%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$46.73
Upside
+ 116.87%
From current price of $21.55 to mean target of $46.73, Based on 18 analyst forecasts
Low
$38.38
Median
$45.90
High
$63.00
Price Target Revisions
1 Month
1.82%
3 Months
93.21%
Price Target Summary
18 analysts have analysed OLMA and the average price target is 46.73 USD. This implies a price increase of 116.87% is expected in the next year compared to the current price of 21.55.
The average price target has been revised upward by 93.21% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
OLMA was analyzed by 18 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about OLMA.
In the previous month the buy percentage consensus was at a similar level.
OLMA was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-11 | Stifel | Initiate | Buy |
| 2026-01-07 | UBS | Initiate | Buy |
| 2026-01-07 | Piper Sandler | Initiate | Overweight |
| 2025-12-12 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-11 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-21 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-11-18 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-11-18 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-08 | Guggenheim | Initiate | Buy |
| 2025-09-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-12 | Citigroup | Maintains | Buy -> Buy |
| 2025-05-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-14 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-19 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$0.54
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-5.74%
Number of Analysts14
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
1.83%
EPS (3 Months)
4.13%
Next Earnings Summary
OLMA is expected to report earnings on 3/16/2026. The consensus EPS estimate for the next earnings is -0.54 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 347.28% | N/A 413.85% | N/A 103.12% | N/A 70.21% | N/A 59.16% | N/A 33.45% | N/A 83.50% | ||||||||
| EBITDA YoY % growth | -2.07M | -4.31M -108.21% | -21.52M -399.30% | -71.33M -231.46% | -106.63M -49.49% | -104.584M 1.92% | -141.865M -35.65% | N/A -21.52% | N/A -22.68% | N/A -12.40% | N/A | N/A | N/A 354.35% | N/A 301.66% | N/A 68.28% | N/A 35.30% | |
| EBIT YoY % growth | -2.08M | -4.32M -107.69% | -21.53M -398.38% | -71.49M -232.05% | -106.99M -49.66% | -104.961M 1.90% | -142.258M -35.53% | N/A -26.56% | N/A -23.40% | N/A -13.20% | N/A 17.69% | N/A 50.12% | N/A 152.23% | N/A 1,149.43% | N/A 49.13% | N/A 28.16% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.80 -71.33% | -2.62 -45.56% | -2.16 17.56% | -2.21 -2.31% | N/A 13.46% | N/A -20.54% | N/A -13.70% | N/A 6.61% | N/A 13.33% | N/A 26.20% | N/A -13.36% | N/A 71.26% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.54 -5.74% | -0.53 -46.98% | -0.59 -16.33% | -0.59 -21.43% | -0.62 -14.62% | -0.72 -35.90% | -0.60 -0.92% | -0.63 -5.09% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -46.478M -27.77% | -46.351M -33.40% | -44.675M 6.15% | -46.409M -1.83% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -49.617M -34.95% | -51.909M -48.85% | -55.664M -16.30% | -56.454M -23.05% | -58.742M -18.39% | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-5.85%
EPS Next 5 Year
0.79%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-17.12%
EBIT Next 5 Year
9.11%
OLEMA PHARMACEUTICALS INC / OLMA Forecast FAQ
What is the price target for OLMA stock?
18 analysts have analysed OLMA and the average price target is 46.73 USD. This implies a price increase of 116.87% is expected in the next year compared to the current price of 21.55.
When does OLEMA PHARMACEUTICALS INC (OLMA) report earnings?
OLEMA PHARMACEUTICALS INC (OLMA) will report earnings on 2026-03-16, after the market close.
What are the consensus estimates for OLEMA PHARMACEUTICALS INC (OLMA) next earnings?
The consensus EPS estimate for the next earnings of OLEMA PHARMACEUTICALS INC (OLMA) is -0.54 USD and the consensus revenue estimate is 0 USD.